Interaction of curcumin on cisplatin cytotoxicity in HeLa and HepG2 carcinoma cells

Abstract

Background and Aims: Our study aimed to evaluate how curcumin affect cisplatin cytotoxicity in human cervical carcinoma (HeLa), human hepatocellular carcinoma (HepG2), and Chinese hamster lung fibroblast (V79) cells. Methods: The cytotoxicity was evaluated by MTT assay. Results: The IC50 values of curcumin were 404 μM and 320 μM in HeLa cells; 236 μM and 98.3 μM in HepG2 cells; 877 μM and 119 μM in V79 cells; for 24 h and 48 h, respectively. The IC50 values of cisplatin were 22.4 μM and 12.3 μM in HeLa cells; 25.5 μM and 7.7 μM in HepG2 cells; 15.4 μM and 4.9 μM in V79 cells; for 24 h and 48 h, respectively. Curcumin significantly decreased cisplatin cytotoxicity at 500 μM in HeLa cells and above 250 μM and 125 μM in HepG2 cells, for 24 h and 48 h, respectively. In V79 cells, curcumin significantly decreased the IC50 values of cisplatin above 500 μM and 125 μM for 24 h and 48 h. Conclusion: The results might contribute to the anticancer effect of the curcumin-cisplatin combination in cervical and hepatocellular carcinoma, but in order to support this result and determine its interactions with antineoplastic drugs, further studies are needed.

Keywords

• Curcumin
• cisplatin
• cytotoxicity
• HeLa cells
• HepG2 cells

References

1. • Abdel-Lateef, E., Mahmoud, F., Hammam, O., El-Ahwany, E., El- Wakıl, E., Kandil, S. … Hassenein H. (2016). Bioactive chemical constituents of Curcuma longa L. rhizomes extract inhibit the growth of human hepatoma cell line (HepG2). Acta pharmaceutica (Zagreb, Croatia), 66, 387–398.
2. • Adahoun, M. A., Al-Akhras, M. H., Jaafar, M. S., & Bououdina, M. (2017). Enhanced anti- cancer and antimicrobial activities of curcumin nanoparticles. Artificial Cells, Nanomedicine and Biotechnology, 45(1), 98–107.
3. • Aggarwal, B., Prasad, S., Sung, B., Krishnan, S., & Guha, S. (2013). Prevention and treatment of colorectal cancer by agents from mother nature. Current Colorectal Cancer Reports, 9(1), 37–56.
4. • Aggarwal, B. B., Kumar, A., & Bharti, A. C. (2003). Anticancer potential of curcumin: Preclinical and clinical studies. Anticancer Research, 23, 363–398.
5. • Anand, P., Kunnumakkara, A. B., Newman, R. A. & Aggarwal, B. B. (2007). Bioavailability of curcumin: problems and promises. Molecular pharmaceutics, 4, 807-818.
6. • Baharuddin, P., Satar, N., Fakiruddin. K. S., Zakaria, N., Lim, M. N., Yusoff, N. M. … Yahaya, B.H. (2016). Curcumin improves the efficacy of cisplatin by targeting cancer stem- like cells through p21 and cyclin D1-mediated tumour cell inhibition in non- small cell lng cancer cell lines. Oncology Reports, 35, 13-25.
7. • Bansal, S. S., Goel, M., Aqil, F., Vadhanam, M. V. & Gupta, R. C. (2011). Advanced drug- delivery systems of curcumin for cancer chemoprevention. Cancer Prevention Research, 4(8), 1158-1171.
8. • Bulboacă, A. E., Porfire, A. S., Tefas, L. R., Boarescu, P. M., Bolboacă, S. D., Stănescu, I. C., Bulboacă, A. C., Dogaru G. (2009). Liposomal curcumin is better than curcumin to alleviate complications in experimental diabetic mellitus. Molecules, 24(5), 846.

9. • Cao, H., Diao, L. M., & Xia, D. (2008). Effects of curcumin combined with cisplatin on the proliferation and apoptosis of human lung cancer cell line A549 in vitro. Medical Journal of Wuhan University, 29, 213–217.
10. • Chen, J., Xu, T., & Chen, C. (2015). The critical roles of miR-21 in anti-cancer effects of curcumin. Annals of Translational Medicine, 3(21), 330–337.
11. • Cheng, Y., Zhao P., Wu, S., Yang, T., Chen, Y., Zhang, X. … Xiang, G. (2018). Cisplatin and curcumin co-loaded nano-liposomes for the treatment of hepatocellular carcinoma. International Journal of Pharmaceutics, 545(1-2), 261–273.
12. • Çıkrıkçı, S., Mozioğlu, E., & Yılmaz, H. (2008). Biological activity of curcuminoids isolated from Curcuma longa. Records of Natural Products, 2(1), 19–24.
13. • Ding, L., Ma, S., Lou, H., Sun, L., & Ji, M. (2015). Synthesis and biological evaluation of curcumin derivatives with water-soluble groups as potential antitumor agents: An in vitro investigation using tumor cell lines. Molecules, 20, 21501–21512.
14. • Dugbartey, G. J., Peppone, L. J., & de Graaf, I. A. (2016). An integrative view of cisplatin- induced renal and cardiac toxicities: Molecular mechanisms, current treatment challenges and potential protective measures. Toxicology, 371, 58–66.
15. • Falzone, L., Salomone, S., & Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Frontiers in Pharmacology, 9, 1300–1326.
16. • Florea, A. M., & Busselberg, D. (2011). Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel), 3(1), 1351–1371.
17. • Gupta, S. C., Patchva, S., & Aggarwal, B. B. (2013). Therapeutic roles of curcumin: Lessons learned from clinical trials. American Association of Pharmaceutical Scientists journal, 15, 195–218.
18. • Guzman, M. N. (2019). Combinations of the antioxidants sulforaphane or curcumin and the conventional antineoplastics cisplatin or doxorubicin as prospects for anticancer chemotherapy. European Journal of Pharmacology, 859, 172513.
19. • Hansen, S. E., & Nielsen, K. B. (1989). Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. Journal of Immunological Methods, 119, 203–210.
20. • Hewlings, S. J., & Kalman, D. S. (2017). Curcumin: A review of its' effects on human health. Foods, 6(10), 92–103.
21. • Koohpar, Z. K., Entezari, M., Movafagh, A., & Hashemi, M. (2015). Anticancer activity of curcumin on human breast adenocarcinoma: role of Mcl-1 gene. Iranian Journal of Cancer Prevention, 8(3), 2331–2335.
22. • Kunnumakkara, A. B., Bordoloi, D., Harsha, C., Banik, K., Gupta, S. C., & Aggarwal, B.B. (2017a). Curcumin mediates anticancer effects by modulating multiple cell signaling pathways. Clinical science (London, England : 1979), 131(15), 1781–1799.
23. • Kunnumakkara, A. B., Bordoloi, D., Padmavathi, G., Monisha, J., Roy, N. K., Prasad, S., & Aggarwal, B. B. (2017b). Curcumin, the golden nutraceutical: Multitargeting for multiple chronic diseases. British Journal of Pharmacology, 174, 1325–1348.
24. • Li, P., Qin, H., & Li, X-J. (2019). The effect of curcumin on the apoptosis of lung cancer cells by regulating DJ-1-PTEN/PI3K/AKT signaling. International journal of Clinical and Experimental Medicine, 12(7), 8739–8745.
25. • Ma, Y., Wang, X., Zong, S., Zhang, Z., Xi.e Z., Huang. Y. … Jing, X. (2015). Local, combination chemotherapy in prevention of cervical cancer recurrence after surgery by using nanofibers co-loaded with cisplatin and curcumin. RSC Advances, 5, 106325–106332.
26. • Menon, V. P., & Sudheer, A. R. (2007). Antioxidant and anti-inflammatory properties of curcumin. Advances in Experimental Medicine and Biology, 595, 105-125.
27. • Moron, B. E., Montano, J. M. C., Salvador, J., Robles, A., & Lazaro, M. L. (2010). The dark side of curcumin. International Journal of Cancer, 126, 1771–1775.
28. • Mosalam, E. M., Zidan, A. A. A., Mehanna, E. T., Mesbah, N. M., & Abo-Elmatty, D. M. (2020). Thymoquinone and pentoxifylline enhance the chemotherapeutic effect of cisplatin by targeting Notch signaling pathway in mice. Life Sciences, 244, 117299.
29. • Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. Journal of Immunological Methods, 65, 55–63.
30. • Nagpal, M., & Sood, D. (2013). Role of curcumin in systemic and oral health: An overview. Journal of Natural Science, Biology and Medicine, 4(1), 3–7.
31. • Nurcahyanti, A. D. R., & Wink, M. (2016). L-Canavanine potentiates the cytotoxicity of doxorubicin and cisplatin in arginine deprived human cancer cells. PeerJ. 4, 1542–1560.
32. • Perrone, D., Ardito, F., Giannatempo, G., Dioguardi, M., Troiano, G., Russo, L. L. … Lo Muzio L. (2015). Biological and therapeutic activities and anticancer properties of curcumin. Experimental and Therapeutic Medicine, 10(5), 1615-1623.
33. • Rosenberg, B. (1985). Fundamental studies with cisplatin. Cancer, 55, 2303–2316.
34. • Roy, M., & Mukherjee, S. (2014). Reversal of resistance towards cisplatin by curcumin in cervical cancer cells. Asian Pacific Journal of Cancer Prevention (APJCP), 15, 1403–1410.
35. • Shehzad, A., Lee, J., & Lee, Y. S. (2013). Curcumin in various cancers. Biofactors, 39(1), 56–68.
36. • Sukumari-Ramesh, S., Bentley, J. N., Laird, M. D., Singh, N., Vender, J. R., Dhandapani, K. M. (2011). Dietary phytochemicals induce p53- and caspase-independent cell death in human neuroblastoma cells. International Journal of Developmental Neuroscience, 29, 701–710.
37. • Taner, G., Aydin, S., Bacanli, M., Sarigol, Z., Sahin, T., Basaran, A. A., & Basaran, N. (2014). Modulating effects of pycnogenol(R) on oxidative stress and DNA damage induced by sepsis in rats. Phytotherapy Research, 28(11), 1692–1700.
38. • Toric, J., Markovic, A. K., Brala, C. J., & Barbaric, M. (2019). Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs. Acta pharmaceutica (Zagreb, Croatia), 69, 461–482.
39. • Wang, Y.-T., Liu, H.-S., & Su, C.-L. (2014). Curcumin-enhanced chemosensitivity of FDA-approved platinum (II)-based anti-cancer drugs involves downregulation of nuclear endonuclease G and NF-κB as well as induction of apoptosis and G2/M arrest. International Journal of Food Sciences and Nutrition, 65, 368–374.
40. • Yang, I. H., Shin, J. A., & Cho, S. D. (2014). Pycnogenol induces nuclear translocation of apoptosis-inducing factor and caspaseindependent apoptosis in MC-3 human mucoepidermoid carcinoma cell line. Journal of Cancer Prevention, 19(4), 265–272.
41. • Zhang, H., Tianyu, Y., Lianji, W., Hui, W., Dan, F., & Chunshun, J. (2013). Curcumin enhances the effectiveness of cisplatin by suppressing CD133+cancer stem cells in laryngeal carcinoma treatment. Experimental and Therapeutic Medicine, 6, 1317–1321.
42. • Zhang, J. R., Lu, F., Lu, T., Dong, W. H., Li, P., Liu, N. ... Ji, C. Y. (2014). Inactivation of FoxM1 transcription factor contributes to curcumininduced inhibition of survival, angiogenesis, and chemosensitivity in acute myeloid leukaemia cells. Journal of Molecular Medicine, 92, 1319–1330.
43. • Zhang, S., Yong, Q., Wu, X., & Liu, X. (2014). [Synergism inhibition of curcumin combined with cisplatin on T24 bladder carcinoma cells and its related mechanism]. Zhong Yao Cai, 37, 2043–2046.
44. • Zou, J., Zhu, L., Jiang, X., Wang, Yang, Wang, Yue, Wang, X., & Chen, B. (2018). Curcumin increases breast cancer cell sensitivity to cisplatin by decreasing FEN1 expression. Oncotarget, 9, 11268– 11278.